トゥレット症候群の世界市場-2022-2029

市場力学

トゥレット症候群の市場成長は、啓発キャンペーンの増加、研究開発の増加、強固なパイプラインなど、いくつかの要因によって推進されています。

トゥレット症候群に関する認知度の向上が、市場の成長を後押ししています。

多くの政府機関や非政府組織が、トゥレット症候群に関する国民の意識形成に向けて取り組んでいます。その1つが、米国トゥレット協会と米国疾病対策予防センター（CDC）が共同で行っている、トゥレットに関する教育・啓発活動を、専門家だけでなく、家族、個人、一般の人々にも提供する取り組みです。このプログラムは、最近「トゥレット健康教育プログラム」（THEP）と改名され、トゥレットに関する情報や教育の共有方法を拡大するために活動しています。トゥレット・アクションのような他の組織は、認知度を高めるためにソーシャルメディアからのサポートを得ています。トゥレット障害啓発デーには、ソーシャルメディアは素晴らしいコミュニケーションツールであるとして、トゥレット・アクションのツィボンをつけたプロファイル写真や、片目を瞬かせたTSelfieに変更するよう、同団体に呼びかけています。国立衛生研究所の発表によると、トゥレット症候群の正確な発症率は不明で、子ども1000人に1人から10人が発症すると予測されています。

特定の薬がないことが、トゥレット症候群の市場成長を妨げています。

薬物療法はチックを完全になくすものではありませんが、日常生活において少数のトゥレット症候群の患者を助けることができます。現在のところ、すべての人に最適な薬物はありません。TSのために処方される薬のほとんどは、チック症の治療薬として米国食品医薬品局（FDA）に承認されていません。

業界の分析

トゥレット症候群市場レポートでは、Porter`s Five forces、研究開発、疫学、規制、価格、パイプライン分析など、さまざまな業界要因に基づいて市場を詳細に分析しますEtc.

COVID-19の影響分析

COVID-19感染拡大の抑制のため、人付き合いが禁止され、ほとんどの研究機関や受託研究センターが閉鎖されたり、半数程度の人員で運営されたりして、進行中の研究活動に影響を及ぼしました。さらに、人付き合いの制限により、症状の理解と改善のためにヘルスケアサポートを求めることが難しくなり、大流行中の世界のトゥレット症候群市場にマイナスの影響を及ぼしました。

トゥレット症候群市場レポートでは、約40以上の市場データ表、45以上の図表、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 啓蒙活動の活発化
    • 研究開発の進展
    • 堅牢なパイプライン
    • 市場戦略
  • 抑制要因
    • 疾患をターゲットとした特定の薬剤がないこと
    • 代替療法の存在
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学分析
• 研究と開発
• パイプライン分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 治療タイプ別

• 抗精神病薬
• 非抗精神病薬

第8章 販売チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第11章 企業プロファイル

• Eli Lilly Company
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• H. Lundbeck A/S
• Emalex Biosciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Therapix Biosciences Ltd.
• Neurocrine Bioscience Inc.
• Reviva Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Janssen Pharmaceuticals
• Mylan N.V.

第12章 DataM

Market Overview

Tourette Syndrome Market is expected to grow at a high CAGR 10.5% during the forecasting period (2022-2029).

Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The early symptoms of the disease are typically noticed in childhood, with the average onset age of three and nine years. Tourette syndrome occurs in people from all ethnic groups; males are affected about three to four times more often than females. According to the National Institute of Neurological Disorders and Stroke, it is estimated that 200,000 Americans have the most severe form of Tourette syndrome and as many as one in 100 exhibits milder and fewer complex symptoms such as chronic motor or vocal tics. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the disease experience their worst tic symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.

Market Dynamics

The Tourette syndrome market growth is driven by several factors, such as a rise in awareness campaigns, an increase in research and development, and a robust pipeline.

The growing awareness about Tourette syndrome is pushing the market growth.

Many government and non-government organizations are working towards creating awareness among the population about Tourette syndrome. One of these initiatives is a joint effort by the Tourette Association of America and the Centers for Disease Control and Prevention (CDC) to provide education and awareness on Tourette to various professional audiences, as well as families, individuals, and the general public. The program, recently renamed "Tourette Health and Education Program" (THEP), works to expand how information and education on Tourette's are shared. Other organizations, such as Tourette's Action, are taking support from social media to increase awareness. On Tourette's Awareness Day, the organization asked people to change their profile pictures with a Tourette's Action twibbon or a TSelfie with one eye blinking, as social media is an incredible communication tool. As per the National Institute of Health, the exact incidence of Tourette's syndrome is uncertain and is predicted to affect 1 to 10 in 1,000 children.

The lack of specific medication is hampering the Tourette Syndrome market growth.

Medications do not terminate tics completely, but they can help a few patients with TS in their daily life. Currently, no one medication is best for all people. Most medications prescribed for TS are not approved by the U.S. Food and Drug Administration (FDA) for treating tics.

Industry analysis.

The Tourette syndrome market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis Etc.

COVID-19 Impact Analysis

For the containment of the COVID-19 infection spread, socializing people was not allowed, which affected the ongoing research activities as most of the research institutes and contract research centers were shut down or were operating on half of their workforce. Furthermore, the socializing restrictions made it difficult for people to seek healthcare support to understand and improve the condition, negatively affecting the global Tourette's syndrome market during the pandemic.

Segment Analysis

Antipsychotic drugs are predicted to command the Tourette syndrome market during the forecast period (2022-2029).

Antipsychotic drugs are expected to hold the largest market share over the forecast period (2022-2029) due to their ability to treat tics to a greater extent thannon-antipsychotic drugs. Antipsychotic drugs were developed for treating schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine, specifically by blocking dopamine receptors, mainly the D2 receptor. Dopamine has been strongly linked with Tourette's syndrome; some of these drugs are the most useful medications for reducing tics. Fluphenazine, haloperidol (Haldol), risperidone (Risperdal), and pimozide (Orap) are the most commonly used antipsychotic drugs for the treatment of Tourette's syndrome. And these medications are reliably quite effective, but they have adverse effects that make other forms of medications and other therapies exist.

Geographical Analysis

The North American region holds the largest market share of the Tourette Syndrome market

North America dominated the Tourette Syndrome market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to high incidences of Tourette syndrome, a highly aware population, advanced healthcare infrastructure, and favorable government initiatives. For instance, One out of 162 children in the U.S. has Tourette's Syndrome, affecting three out of every 1000 children between the ages of 6 and 17. Moreover, the estimation by the Child Development and Disability Branch, Division of Human Development and Disability, the CDC, Atlanta, GA, USA using data from the 2020 U.S. census, estimated that around 350,000-450,000 Americans living with Tourette syndrome and over 1 million have other persistent tic disorders. Furthermore, many government and non-government organizations are working towards raising awareness among the common population, such as The American Academy of Neurology (AAN) is the world's largest association of neurologists and neuroscience professionals, with over 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care to Tourette's patients.

Competitive Landscape

Some of the major key players in the market are H. Lundbeck A/S, Emalex Biosciences, Inc., Teva Pharmaceutical Industries Ltd., Therapix Biosciences Ltd., Neurocrine Bioscience Inc., Eli Lilly and Company, Reviva Pharmaceuticals Inc., Bausch Health Companies Inc., Janssen Pharmaceuticals, and Mylan N.V. In the Tourette Syndrome market, H. Lundbeck A/S holds the leadership position due to robust pipeline, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations, and increasing research and development and high investment, contributing to the growth of the Tourette Syndrome market globally. For instance, on November 10, 2021, Emalex Biosciences Announced positive topline results of phase 2b clinical trial of ecopipam for pediatric Tourette syndrome. Also, on 10 February 2021, SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) entered an agreement with Procaps for the development and production of CannAmide and its SCI-110 product candidate

Eli Lilly Company

Overview

Eli Lilly company was founded in 1876 in Indianapolis, Indiana, U.S. and named after Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. It has its products sold in around 125 countries all around the world. Eli Lilly is pursuing bold advancements in medicine and pushing to close the gaps in health care inequality.

Product Portfolio

Eli Lilly's product portfolio for Tourette Syndrome has Strattera (atomoxetine) capsules (10, 18, 25, 40, 60, 80, and 100 mg capsules).

The Tourette syndrome market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise In Awareness Campaigns
    • 4.1.1.2. Research and Development
    • 4.1.1.3. Robust Pipeline
    • 4.1.1.4. Market Strategies
  • 4.1.2. Restraints
    • 4.1.2.1. No Particular Drug Targeting the Disease
    • 4.1.2.2. Presence of Alternate Therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiological Analysis
• 5.3. Research and Developments
• 5.4. Pipeline Analysis
• 5.5. Supply Chain Analysis
• 5.6. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
  • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
• 7.2. Antipsychotic Drugs
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Non-Antipsychotic Drugs

8. By Distribution Channels

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
  • 8.1.2. Market Attractiveness Index, By Distribution Channels Segment
• 8.2. Hospital Pharmacy
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Retail Pharmacy
• 8.4. Online Pharmacy

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. The U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. Australia
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking

11. Company Profiles

• 11.1. Eli Lilly Company
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. H. Lundbeck A/S
• 11.3. Emalex Biosciences, Inc.
• 11.4. Teva Pharmaceutical Industries Ltd.
• 11.5. Therapix Biosciences Ltd.
• 11.6. Neurocrine Bioscience Inc.
• 11.7. Reviva Pharmaceuticals Inc.
• 11.8. Bausch Health Companies Inc.
• 11.9. Janssen Pharmaceuticals
• 11.10. Mylan N.V.

LIST NOT EXHAUSTIVE

12. DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact